Clinical Policy: Abaloparatide (Tymlos)
Customize your policy alerts
Sign up for all Health Net policy alerts
Know when Health Net releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing medical necessity, prior authorization, and coverage criteria for abaloparatide (Tymlos) for treatment of postmenopausal and male osteoporosis for Health Net lines of business (Commercial, HIM, Medicaid). Applies to providers requesting coverage under the plan.
Added newly approved indication of male osteoporosis to criteria.
Revised initial approval duration to 12 months for Medicaid/HIM and added Commercial approval duration of 6 months or to the member's renewal date, whichever is longer.
Clarified failure of generic alendronate is preferred and clarified dosage regimen.
Added option to bypass bisphosphonate trial if member has experienced loss of BMD, lack of BMD increase, or had an osteoporotic/fragility fracture while on bisphosphonate therapy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.